Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.93 |
| ▸ | OR51E2 | Q9H255 | 2/20 | 0.93 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.93 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.93 |
| ▸ | LMNA | P02545 | 6/20 | 0.60 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.60 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.60 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.45 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | KDM5C | P41229 | 2/20 | 0.41 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.41 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.41 |
| ▸ | KDM6B | O15054 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.41 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alpha-Ketoglutaric Acid SCHEMBL30208560 | 0.97 | EGLN1 (1.00) | EGLN1OR51E2MAPK1SLC13A3LMNA | |
| Alpha-Ketoglutaric Acid SCHEMBL29783374 | 0.97 | EGLN1 (1.00) | EGLN1OR51E2MAPK1SLC13A3LMNA | |
| Alpha-Ketoglutaric Acid SCHEMBL30029036 | 0.97 | EGLN1 (1.00) | EGLN1OR51E2MAPK1SLC13A3LMNA | |
| Alpha-Ketoglutaric Acid SCHEMBL17127347 | 0.97 | EGLN1 (1.00) | EGLN1OR51E2MAPK1SLC13A3LMNA | |
| Alpha-Ketoglutaric Acid SCHEMBL3776640 | 0.97 | EGLN1 (1.00) | EGLN1OR51E2MAPK1SLC13A3LMNA | |
| Alpha-Ketoglutaric Acid SCHEMBL932116 | 0.97 | EGLN1 (1.00) | EGLN1OR51E2MAPK1SLC13A3LMNA | |
| Alpha-Ketoglutaric Acid SCHEMBL7400 | 0.97 | EGLN1 (1.00) | EGLN1OR51E2MAPK1SLC13A3LMNA | |
| Alpha-Ketoglutaric Acid SCHEMBL1242830 | 0.93 | EGLN1 (0.93) | EGLN1OR51E2MAPK1SLC13A3LMNA | |
| Alpha-Ketoglutaric Acid SCHEMBL1428274 | 0.93 | EGLN1 (0.93) | EGLN1OR51E2MAPK1SLC13A3LMNA | |
| Alpha-Ketoglutaric Acid SCHEMBL20594156 | 0.93 | EGLN1 (0.93) | EGLN1OR51E2MAPK1SLC13A3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117838923-A | Preparation method and application of tricarboxylic acid circulating metabolite salt ion modified bone repair hydrogel | 成都云淇生命科技有限公司 | 2024-04-09 | — | — | CN | claimed |
| US-11504351-B2 | Methods for restoring stem cell pools and reducing epigenetic age | DISCHLER LOUIS (US) | 2022-11-22 | — | — | US | claimed |
| US-20220257558-A1 | METHODS FOR RESTORING STEM CELL POOLS AND REDUCING EPIGENETIC AGE | DISCHLER LOUIS (US) | 2022-08-18 | — | — | US | claimed |
| US-11344528-B2 | Compositions for promoting the endogenous self-renewal of stem cells | DISCHLER LOUIS (US) | 2022-05-31 | — | — | US | claimed |
| US-11324764-B2 | Methods for reducing mitochondrial dysfunction | DISCHLER LOUIS (US) | 2022-05-10 | — | — | US | claimed |
| CN-113956152-A | Preparation method of alpha-ketoglutaric acid magnesium salt | 上海凝璇企业管理合伙企业(有限合伙) | 2022-01-21 | — | — | CN | claimed |
| US-11090320-B2 | Compositions for reducing mitochondrial dysfunction | DISCHLER LOUIS (US) | 2021-08-17 | — | — | US | claimed |
| US-20210186922-A1 | METHODS AND COMPOSITIONS FOR REDUCING EPIGENETIC AGE AND MITOCHONDRIAL DYSFUNCTION | DISCHLER LOUIS (US) | 2021-06-24 | — | — | US | claimed |
| US-20210161925-A1 | METHODS AND COMPOSITIONS FOR REDUCING EPIGENETIC AGE AND MITOCHONDRIAL DYSFUNCTION | DISCHLER LOUIS (US) | 2021-06-03 | — | — | US | claimed |
| US-20190151275-A1 | COMPOSITION FOR TREATMENT OF NEURODEGENERATIVE DISEASE | TEDONE 3G LLC | 2019-05-23 | — | — | US | claimed |
| US-20150328176-A1 | COMPOSITION FOR TREATMENT OF NEURODEGENERATIVE DISEASE | WINNING THE FIGHT INC. (US) | 2015-11-19 | — | — | US | claimed |
| US-20250221952-A1 | METHODS AND COMPOSITIONS FOR LARGE MODIFICATIONS OF ATP OUTPUT BY INNER MITOCHONDRIAL MEMBRANE LATCHING | DISCHLER LOUIS (US) | 2025-07-10 | — | — | US | disclosed |
| US-20250082597-A1 | METHOD FOR TREATING TAUOPATHY IN THE BRAIN, BRAIN STEM AND SPINAL COLUMN | TEDONE 3G LLC (US) | 2025-03-13 | — | — | US | disclosed |
| CN-117838923-A | Preparation method and application of tricarboxylic acid circulating metabolite salt ion modified bone repair hydrogel | 成都云淇生命科技有限公司 | 2024-04-09 | — | — | CN | disclosed |
| US-11541022-B2 | Methods and compositions for the treatment of neurological diseases and syndromes of aging | DISCHLER LOUIS (US) | 2023-01-03 | — | — | US | disclosed |
| US-20010031744-A1 | Compositions and methods for prevention and treatment of chronic diseases and disorders including the complications of diabetes mellitus | KOSBAB JOHN V (US) | 2001-10-18 | — | — | US | disclosed |
| EP-1100517-A1 | NUTRIENT AND THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF CANCER | Kosbab, John V. (US) | 2001-05-23 | — | — | EP | disclosed |
| EP-1021177-A1 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF VASCULAR DEGENERATIVE DISEASES | Kosbab, John V. (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-2000007607-A1 | NUTRIENT AND THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF CANCER | KOSBAB, JOHN, V. (US) | 2000-02-17 | — | — | WO | disclosed |
| WO-1998033494-A1 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF VASCULAR DEGENERATIVE DISEASES | KOSBAB JOHN V (US) | 1998-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250082597-A1 | METHOD FOR TREATING TAUOPATHY IN THE BRAIN, BRAIN STEM AND SPINAL COLUMN | BCKDK, ATXN10, SLC1A2 | EGLN1 1307/4885OR51E2 4725/4885MAPK1 4026/4885 |
| US-20190151275-A1 | COMPOSITION FOR TREATMENT OF NEURODEGENERATIVE DISEASE | ATXN10, SLC25A20, BCKDK | EGLN1 738/4885OR51E2 4324/4885MAPK1 3805/4885 |
| US-20250221952-A1 | METHODS AND COMPOSITIONS FOR LARGE MODIFICATIONS OF ATP OUTPUT BY INNER MITOCHONDRIAL MEMBRANE LATCHING | SHMT2, TUFM, TFB2M | EGLN1 436/4885OR51E2 4699/4885MAPK1 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.